Conference - London, United Kingdom
Europe's Largest Translational Epigenetics Meeting
As the bridge between genotype and phenotype, the field of epigenetic research has enormous potential to progress diagnosis and therapy in oncology and the wider disease spectrum.
Are you prepared for the leap forward in epigenetic therapeutics?
Realizing such immense potential will require thought leaders to address very specific challenges. Calls to action are being made to identify and validate new epigenetic drug targets for oncological, autoimmune and inflammatory diseases. Industry and academia also agree that more must be done to productively integrate recent advances in the basic and clinical sciences.
With strong representation and candid discussion guaranteed from senior level figures at GSK, the Structural Genomics Consortium, Constellation Pharmaceuticals and Epizyme, the 4th World Epigenetics Summit will address these issues directly and deliver commercially directed insight into the most pressing technical and strategic issues at hand.
The 4th World Epigenetics Summit provides a unique platform on which senior representatives from GSK, Constellation and Epizyme share ideas with leading academic figures such as Tony Kouzarides and Chas Bountra. In bringing together the minds behind the most exciting drugs in development, the meeting represents two days dedicated to overcoming the most pressing challenges in epigenetic drug development.
(Courtesy of London, btvnews.bg)
Tuesday, December 4, 2012 to Tuesday, December 6, 2012
Doubletree by Hilton Hotel London – West End
92 Southampton Row, London, United Kingdom
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
